eXoZymes, Inc. (EXOZ) Stock Forecast

NASDAQ: EXOZAnalyst ratings, price target and estimates.

EXOZ analyst forecast

as of October 18, 2026
Analyst consensus
—
Price target
—
average of analyst targets
Upside to target
—
from the latest close
Next earnings
November 12, 2026
52-week range
$4.00 – $16.50

EXOZ earnings per share estimates

eXoZymes, Inc. EPS estimates
PeriodAverageLowHighYear agoGrowthAnalysts
Current fiscal year (2026)−$1.19−$1.19−$1.19−$1.09−9.2%1
Next fiscal year (2027)−$1.12−$1.12−$1.12−$1.19+5.9%1

Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.

EXOZ revenue estimates

eXoZymes, Inc. revenue estimates
PeriodAverageLowHighGrowthAnalysts
Current fiscal year (2026)$0$0$0—1
Next fiscal year (2027)$540,000$540,000$540,0000.0%1

EXOZ EPS: reported and forecast

Reported EPSEstimate (average; low–high)

Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.

EXOZ revenue: reported and forecast

Reported revenueEstimate (average; low–high)

EXOZ EPS estimate revisions

eXoZymes, Inc. EPS estimate revisions
Period90 days ago60 days ago30 days ago7 days agoNowChange (90 d)Revisions (30 d)
Current fiscal year (2026)$0.00$0.00$0.00$0.00−$1.19—0 up · 0 down
Next fiscal year (2027)$0.00$0.00$0.00$0.00−$1.12—0 up · 0 down

How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.

EXOZ earnings surprises

Reported EPSEstimate

What analysts expect from EXOZ

Analysts expect earnings of −$1.19 per share for 2026, −9.2% from a year earlier. For 2027 the average estimate is −$1.12 per share on revenue of $0.5 million.

Related: EXOZ income statement, EXOZ key metrics, EXOZ chart. See the EXOZ stock overview for the latest quote and news.

EXOZ forecast FAQ

What is eXoZymes's EPS forecast?

Analysts forecast −$1.19 per share for 2026 (range −$1.19 to −$1.19); for 2027 the estimate is −$1.12.

When does eXoZymes report earnings?

eXoZymes is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.

Biotechnology: forecast